about
New players in the preventive treatment of migraineImmunogenicity of mAbs in non-human primates during nonclinical safety assessmentComprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells.Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodiesPeptide-based targeting of the platelet-derived growth factor receptor beta.Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.In-vitro suppression of IL-6 and IL-8 release from human pulmonary epithelial cells by non-anticoagulant fraction of enoxaparinThe 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' OrbitopathySeverity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.The advent of monoclonal antibodies in the treatment of chronic autoimmune diseases.Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders.Postoperative eyelid infection in a patient taking etanercept.The yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk.Advances and applications of molecular cloning in clinical microbiology.Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.CGRP mechanism antagonists and migraine management.Novel Therapies for Thyroid Autoimmune Diseases.Anti-drug antibodies in Colombian patients with rheumatoid arthritis treated with Enbrel vs Etanar - Preliminary report.Chronic migraine treatment: from OnabotulinumtoxinA onwards.Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.Palivizumab Exposure and the Risk of Autoimmune Disease: A Cross-National Cohort Study.Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.Effects of enteral immunonutrition on immune function in patients with multiple trauma.Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.T-cell-dependent antibody responses in the rat: forms and sources of keyhole limpet hemocyanin matter.Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.Development of a flowchart for risk assessment and allocation of preparation of monoclonal antibodies.Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab.The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab.Nerve-targeted probes for fluorescence-guided intraoperative imagingCombination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor
P2860
Q26778185-8E50495A-1697-4F78-9B49-3875049D6E50Q30390955-73726DBC-C22A-429D-BA7A-215B1BD9EAF4Q33893235-0CB67203-C5F4-44F5-AE34-B7772E208DEDQ33895804-D737D787-6FEA-41AA-B3F8-A1B512E97F35Q34335171-E5667F4D-37A1-4930-8772-66B9CA99ABBDQ35055076-19EA5FA7-8540-424E-BB24-F32D52F99773Q35626866-775E5DC9-DE6B-4AC7-8BF0-65CF66043251Q36811289-227FDC15-5CDD-4F6C-8200-C95F5677A5A1Q37064758-DB0BF1EA-BEF4-431A-8685-F0F1C494C947Q37138974-7E079071-2933-4824-A7DA-8B9C4658154EQ37774281-1FAF7C5D-58DF-4D52-9D48-377ECD342844Q37923355-E1636E14-9198-4285-A46B-97A36ECD7E24Q37963464-CCC7199E-2FD5-45C2-A279-C15FB5FAAD4EQ37973651-91A61E92-747E-4274-BD7A-31C13E511DB9Q38229428-27FFEBC8-6D40-4D6C-B4EF-0974D4052AF7Q38357886-0CCA4A27-09F7-4CBB-9219-141051549447Q38384223-9356C8AB-D993-423F-8707-BB3E02FBEC45Q38743624-F8446A4B-9B3D-4CD5-BF5C-D2BD395C88D3Q38826191-1A23CD36-B2A4-4937-B10D-8123A76DC98FQ38866988-0B512C42-3E2D-4AB8-BE6E-29A72CDF4ADEQ39242677-6FEB17D4-1870-42EA-9F74-24C9ABE90770Q39354106-79AB1E2B-DBC1-4702-8336-363F943BC428Q39913293-BE96BDBD-2002-4906-BC01-AE5378DDF08EQ41833962-B45D5BF8-1D4C-444B-A5AC-0750F4BBA751Q46453213-5271259E-A703-4718-9A71-CD559C75F383Q47739573-13488590-7971-43AD-8DF0-F281C58E6CA5Q47942947-6D97542D-C737-442E-B4E2-02847133D02AQ49041967-6701A53B-8949-4171-B9B6-956C13DBFB4DQ50214755-7CB0C031-08B7-4775-B688-EA95E9804110Q50935053-01AEDC07-318D-402A-941E-96C7DDF47A2DQ56888900-1D752279-C492-41EC-B72B-9E886621CEFAQ57137831-56ACB869-EFE5-4191-A135-CF7E82DAAB37
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Immunotoxicity of monoclonal antibodies
@ast
Immunotoxicity of monoclonal antibodies
@en
Immunotoxicity of monoclonal antibodies
@nl
type
label
Immunotoxicity of monoclonal antibodies
@ast
Immunotoxicity of monoclonal antibodies
@en
Immunotoxicity of monoclonal antibodies
@nl
prefLabel
Immunotoxicity of monoclonal antibodies
@ast
Immunotoxicity of monoclonal antibodies
@en
Immunotoxicity of monoclonal antibodies
@nl
P2860
P356
P1476
Immunotoxicity of monoclonal antibodies
@en
P2093
Jacques Descotes
P2860
P304
P356
10.4161/MABS.1.2.7909
P407
P577
2009-01-01T00:00:00Z